{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T05:11:17Z","timestamp":1736485877734,"version":"3.32.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1097\/01.bor.0000231902.27419.64","type":"journal-article","created":{"date-parts":[[2006,6,7]],"date-time":"2006-06-07T18:12:58Z","timestamp":1149703978000},"page":"354-358","source":"Crossref","is-referenced-by-count":0,"title":["Clinical assessment in the spondyloarthropathies, including psoriatic arthritis"],"prefix":"10.1097","volume":"18","author":[{"given":"Filip","family":"Van den Bosch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bert","family":"Vander Cruyssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman","family":"Mielants","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.1780341003","article-title":"The European spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy","volume":"34","author":"Dougados","year":"1991","journal-title":"Arthritis Rheum"},{"key":"R2-6-20210128","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11926-996-0039-x","article-title":"Outcome measures in psoriatic arthritis","volume":"7","author":"Kavanaugh","year":"2005","journal-title":"Curr Rheumatol Rep"},{"key":"R3-6-20210128","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"R4-6-20210128","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"R5-6-20210128","first-page":"302","article-title":"Evaluation of a functional index and an articular index in ankylosing spondylitis","volume":"15","author":"Dougados","year":"1988","journal-title":"J Rheumatol"},{"key":"R6-6-20210128","first-page":"961","article-title":"A comparative study of the usefulness of the BASFI and the DFI in the assessment of AS","volume":"26","author":"Spoorenberg","year":"1999","journal-title":"J Rheumatol"},{"key":"R7-6-20210128","first-page":"1694","article-title":"Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index","volume":"21","author":"Jenkinson","year":"1994","journal-title":"J Rheumatol"},{"key":"R8-6-20210128","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","article-title":"First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R9-6-20210128","first-page":"80","article-title":"Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study","volume":"32","author":"Pavy","year":"2005","journal-title":"J Rheumatol"},{"key":"R10-6-20210128","first-page":"2225","article-title":"Preliminary core sets for endpoints in ankylosing spondylitis","volume":"24","author":"Van der Heijde","year":"1997","journal-title":"J Rheumatol"},{"key":"R11-6-20210128","first-page":"951","article-title":"Selection of instruments in the core set for DC-ART, SMARD, physical therapy and clinical record keeping in AS: progress report of the ASAS Working Group","volume":"26","author":"Van der Heijde","year":"1999","journal-title":"J Rheumatol"},{"key":"R12-6-20210128","first-page":"1609","article-title":"A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI)","volume":"22","author":"Jones","year":"1995","journal-title":"J Rheumatol"},{"issue":"9 Suppl","key":"R13-6-20210128","first-page":"S635","article-title":"Bath Ankylosing Spondylitis Metrology Index (BASMI): 3-point and 11-point answering scales are not interchangeable","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R14-6-20210128","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/ard.2003.016717","article-title":"Development and preselection of criteria for short term improvement after anti-TNFa treatment in ankylosing spondylitis","volume":"63","author":"Brandt","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R15-6-20210128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.61.3.207","article-title":"Repeated infusions of infliximab, a chimeric anti-TNF\u03b1 monoclonal antibody, in patients with active spondyloarthropathy: one year follow up","volume":"61","author":"Kruithof","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R16-6-20210128","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/rheumatology\/41.11.1280","article-title":"Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study","volume":"41","author":"Breban","year":"2002","journal-title":"Rheumatology"},{"key":"R17-6-20210128","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","article-title":"Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum"},{"key":"R18-6-20210128","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R19-6-20210128","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.berh.2003.09.011","article-title":"Are better endpoints and better design of clinical trials needed?","volume":"18","author":"Fransen","year":"2004","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R20-6-20210128","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1136\/ard.2004.030924","article-title":"Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial","volume":"64","author":"Fransen","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R21-6-20210128","first-page":"579","article-title":"Development of a disease activity score based on judgment in clinical practice by rheumatologists","volume":"20","author":"van der Heijde","year":"1993","journal-title":"J Rheumatol"},{"key":"R22-6-20210128","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"9 Suppl","key":"R23-6-20210128","first-page":"S214","article-title":"Efficacy of adalimumab in psoriatic arthritis as measured by the disease activity score 28","volume":"52","author":"Choy","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R24-6-20210128","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/ard.46.3.197","article-title":"Studies with an enthesitis index as a method of clinical assessment in ankylosing spondylitis","volume":"46","author":"Mander","year":"1987","journal-title":"Ann Rheum Dis"},{"key":"R25-6-20210128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.62.2.127","article-title":"Assessment of enthesitis in ankylosing spondylitis","volume":"62","author":"Heuft-Dorenbosch","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R26-6-20210128","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"R27-6-20210128","first-page":"1126","article-title":"The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada","volume":"31","author":"Gladman","year":"2004","journal-title":"J Rheumatol"},{"issue":"Suppl 6","key":"R28-6-20210128","first-page":"1416","article-title":"Characteristics of dactylitis in psoriatic arthritis","volume":"28","author":"Brockbank","year":"2001","journal-title":"J Rheumatol"},{"key":"R29-6-20210128","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R30-6-20210128","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of Infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis. Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R31-6-20210128","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"for the Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"Suppl II","key":"R32-6-20210128","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1136\/ard.2004.033654","article-title":"Seronegative spondyloarthropathies: to lump or split?","volume":"64","author":"Nash","year":"2005","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.bor.0000231902.27419.64","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T07:42:03Z","timestamp":1736408523000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-200607000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.bor.0000231902.27419.64","relation":{},"ISSN":["1040-8711"],"issn-type":[{"type":"print","value":"1040-8711"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}